Information Provided By:
Fly News Breaks for June 19, 2018
NKTR, BMY, MDGL
Jun 19, 2018 | 07:54 EDT
As previously reported, Evercore ISI analyst Josh Schimmer downgraded Madrigal Pharmaceuticals (MDGL) to In Line from Outperform, stating that he has no real incremental reason to raise his $300 price target, which the stock has achieved following the company's encouraging Phase 2 results for MGL-3196 and a Bloomberg report that has driven takeover speculation. Given current investor sentiment, anything short of either an acquisition or a "massive" collaboration like Bristol-Myers' (BMY) with Nektar (NKTR) will fall short of expectations, Schimmer tells investors.
News For MDGL;BMY;NKTR From the Last 2 Days
There are no results for your query MDGL;BMY;NKTR